A Phase 2 interventional study of gemcitabine and doxorubicin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 3 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-27.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 48th largest by enrollment of the 90 interventional ones that give a count, is one of 7 that started in 2003, is one of 65 in phase 2, and was the 22nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 7 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 62nd largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2003, is one of 41 in phase 2, and was the 11th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Gemcitabine and anthracycline combination has shown encouraging activity as neoadjuvant chemotherapy in locally advanced breast cancer. An addition of sequential gemcitabine and cisplatin, also a highly active combination in this indication, may result in improvement in pathological response and overall survival. Patients with operable breast cancer will be treated in neoadjuvant setting with gemcitabine plus doxorubicin, followed by gemcitabine plus cisplatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemcitabine: 1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8). Doxorubicin: 60 mg/m\^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m\^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
Drug: gemcitabine · Drug: doxorubicin · Drug: cisplatin · Procedure: surgery
1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
Also known as: LY188011, Gemzar
60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)
Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)
Complete pathological response: No invasive tumor cells identified from sections from site of previous cancer. Require evidence corroborating prior presence of invasive cancer, which requires detection of abnormal fibroelastic breast stroma devoid of normal lobular units and contains foamy macrophages with moderate numbers of fibroblasts and mononuclear inflammatory cells. Presence of nondescript collagenised lobules or breast fibrous tissue is not evidence that tumor site has been adequately sampled and macroscopic assessment and sampling is needed until original neoplastic stroma identified.
Time frame: tumor assessment at baseline and during surgery after eight 21-day treatment cycles
Summary of Deaths During Study
Time frame: baseline through last cycle on study drug (eight 21-day cycles)
Progression Free Survival (PFS)
PFS was defined as the date of enrollment to the first date of documented disease progression or death from any cause. Because the median was not reached, results are presented as the Outcome: Number of Participants with Disease Progression or Death at Various Timepoints.
Time frame: baseline to measured progressive disease or death from any cause (up to 68 months)
Overall Survival
Overall survival was defined as the date of enrollment to the date of death from any cause. Because the median was not reached, results will be presented as the Outcome: Number of Participants who Died from Any Cause at Various Timepoints.
Time frame: baseline to date of death from any cause up to 68 months
Time to Treatment Failure
Time to treatment failure was defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed. Because the upper limit of the 95% Confidence Interval of median survival was not calculable, results are presented as the Outcome: Number of Participants with Time to Treatment Failure at Various Timepoints.
Time frame: baseline to stopping treatment (up to 68 months)
Number of Patients Eligible for Breast Conservation Surgery at Baseline and Number of Patients Undergoing Breast Conservation Surgery
The extent and type of surgery was guided by the tumor size, physician and/or patient decision. It was either conservation surgery or mastectomy with axillary lymph node dissection. Results are reported on the number of patients who underwent breast conservation surgery.
Time frame: baseline, after eight 21-day cycles of study drug
| Milestone | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Started | 65 |
| Completed | 40 |
| Not completed | 25 |
| Withdrew: Adverse event | 5 |
| Withdrew: Patient: satisfactory response | 5 |
| Withdrew: Patient/physician: satisfactory response | 4 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Death - possibly study drug related | 4 |
| Withdrew: Progressive disease/lack of efficacy | 2 |
| Withdrew: Death - not study-drug related | 1 |
Complete pathological response: No invasive tumor cells identified from sections from site of previous cancer. Require evidence corroborating prior presence of invasive cancer, which requires detection of abnormal fibroelastic breast stroma devoid of normal lobular units and contains foamy macrophages with moderate numbers of fibroblasts and mononuclear inflammatory cells. Presence of nondescript collagenised lobules or breast fibrous tissue is not evidence that tumor site has been adequately sampled and macroscopic assessment and sampling is needed until original neoplastic stroma identified.
| participants | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Number of Patients With Pathological Complete Response (Pathological Complete Response Rate) | 13 |
| participants | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Study Disease | 0 |
| Study Drug Toxicity: Cardiac arrest | 1 |
| Study Drug Toxicity: Infection with neutropenia | 1 |
| Study Drug Toxicity: Neutropenic sepsis | 2 |
| Myocardial infarction | 1 |
PFS was defined as the date of enrollment to the first date of documented disease progression or death from any cause. Because the median was not reached, results are presented as the Outcome: Number of Participants with Disease Progression or Death at Various Timepoints.
No measurements were reported for this outcome.
Overall survival was defined as the date of enrollment to the date of death from any cause. Because the median was not reached, results will be presented as the Outcome: Number of Participants who Died from Any Cause at Various Timepoints.
No measurements were reported for this outcome.
Time to treatment failure was defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed. Because the upper limit of the 95% Confidence Interval of median survival was not calculable, results are presented as the Outcome: Number of Participants with Time to Treatment Failure at Various Timepoints.
No measurements were reported for this outcome.
The extent and type of surgery was guided by the tumor size, physician and/or patient decision. It was either conservation surgery or mastectomy with axillary lymph node dissection. Results are reported on the number of patients who underwent breast conservation surgery.
| participiants | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Eligible for Surgery at Baseline | 0 |
| Underwent Surgery | 18 |
The cumulative number of participants with an event (either progressive disease or death) are presented at various time points, as well as the number of participants at risk for the event. Participants at risk are the number of participants without progressive disease or still alive at the beginning of each time point.
| participants | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| 3 Months: Number of Patients with Event | 5 |
| 3 Months: Number of Patients at Risk | 59 |
| 6 Months: Number of Patients with Event | 8 |
| 6 Months: Number of Patients at Risk | 50 |
| 12 Months: Number of Patients with Event | 11 |
| 12 Months: Number of Patients at Risk | 41 |
| 24 Months: Number of Patients with Event | 15 |
| 24 Months: Number of Patients at Risk | 36 |
| 48 Months: Number of Patients with Event | 21 |
| 48 Months: Number of Patients at Risk | 23 |
| 68 Months: Number of Patients with Event | 21 |
| 68 Months: Number of Patients at Risk | 1 |
The cumulative number of participants with an event (death from any cause) are presented at various time points, as well as the number of participants at risk for the event. Participants at risk are the number of participants still alive at the beginning of each time point.
| participants | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| 3 Months: Number of Patients With Event | 3 |
| 3 Months: Number of Patients at Risk | 60 |
| 6 Months: Number of Patients With Event | 5 |
| 6 Months: Number of Patients at Risk | 51 |
| 12 Months: Number of Patients With Event | 7 |
| 12 Months: Number of Patients at Risk | 43 |
| 26 Months: Number of Patients With Event | 11 |
| 26 Months: Number of Patients at Risk | 37 |
| 48 Months: Number of Patients With Event | 14 |
| 48 Months: Number of Patients at Risk | 24 |
| 68 Months: Number of Patients With Event | 15 |
| 68 Months: Number of Patients at Risk | 1 |
This outcome is in place of the time to treatment failure outcome. The cumulative number of participants with an event (disease progression, death as a result of any cause, or early discontinuation of treatment) are presented at various time points, as well as the number of participants at risk for the event. Participants at risk are the number of participants without disease progression, are alive, or did not discontinue treatment early at the beginning of each time point.
| participants | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| 3 Months: Number of Patients with Event | 11 |
| 3 Months: Number of Patients at Risk | 59 |
| 6 Months: Number of Patients with Event | 19 |
| 6 Months: Number of Patients at Risk | 50 |
| 12 Months: Number of Patients with Event | 25 |
| 12 Months: Number of Patients at Risk | 41 |
| 24 Months: Number of Patients with Event | 29 |
| 24 Months: Number of Patients at Risk | 36 |
| 48 Months: Number of Patients with Event | 35 |
| 48 Months: Number of Patients at Risk | 23 |
| 68 Months: Number of Patients with Event | 35 |
| 68 Months: Number of Patients at Risk | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine+Doxorubicin+Cisplatin+Surgery | — | 17/65 (26.2%) | 64/65 (98.5%) |
| Event | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Neutropenic sepsisInfections and infestations | 6/65 |
| DiarrhoeaGastrointestinal disorders | 5/65 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/65 |
| NeutropeniaBlood and lymphatic system disorders | 2/65 |
| Cardiac arrestCardiac disorders | 2/65 |
| VomitingGastrointestinal disorders | 2/65 |
| Neutropenic infectionInfections and infestations | 2/65 |
| PancytopeniaBlood and lymphatic system disorders | 1/65 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/65 |
| Myocardial infarctionCardiac disorders | 1/65 |
| Event | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 57/65 |
| NeutropeniaBlood and lymphatic system disorders | 45/65 |
| LeukopeniaBlood and lymphatic system disorders | 42/65 |
| Aspartate aminotransferase increasedInvestigations | 27/65 |
| Alanine aminotransferase increasedInvestigations | 26/65 |
| AlopeciaSkin and subcutaneous tissue disorders | 26/65 |
| ThrombocytopeniaBlood and lymphatic system disorders | 17/65 |
| FatigueGeneral disorders | 15/65 |
| StomatitisGastrointestinal disorders | 13/65 |
| VomitingGastrointestinal disorders | 13/65 |
| Age Continuous(years) | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Median | 46 (31 to 70) |
| Sex: Female, Male(Participants) | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Female | 65 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Indian | 65 |
| Region of Enrollment(participants) | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| India | 65 |
| Diagnosis(participants) | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Histopathological | 12 |
| Cytological | 53 |
| Disease Stage(participants) | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| Stage IIA | 3 |
| Stage IIB | 30 |
| Stage IIIA | 18 |
| Stage IIIB | 14 |
| Hormone Receptor Status(participants) | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| ER+ / PR+ | 27 |
| ER+ / PR- | 8 |
| ER- / PR+ | 3 |
| ER- / PR- | 25 |
| No Assessment | 2 |
| Human Epidermal Growth Factor Receptor 2 (HER-2) Status(participants) | Gemcitabine+Doxorubicin+Cisplatin+Surgery |
|---|---|
| 0 | 27 |
| 1+ | 8 |
| 2+ | 2 |
| 3+ | 19 |
| Not Detected | 7 |
| Insufficient Sample | 2 |
6 further baseline measures are reported on the registry.
The record gives a start of Feb 2003, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Doxorubicin · Cisplatin